These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3840382)

  • 1. In vitro degradation of atracurium in human plasma.
    Stiller RL; Cook DR; Chakravorti S
    Br J Anaesth; 1985 Nov; 57(11):1085-8. PubMed ID: 3840382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma.
    Welch RM; Brown A; Ravitch J; Dahl R
    Clin Pharmacol Ther; 1995 Aug; 58(2):132-42. PubMed ID: 7648763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium?
    Weindlmayr-Goettel M; Gilly H; Kress HG
    Br J Anaesth; 2002 Apr; 88(4):555-62. PubMed ID: 12066733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of atracurium, laudanosine and related compounds in plasma by high-performance liquid chromatography.
    Simmonds RJ
    J Chromatogr; 1985 Oct; 343(2):431-6. PubMed ID: 3840807
    [No Abstract]   [Full Text] [Related]  

  • 5. Atracurium decay and the formation of laudanosine in humans.
    Nigrovic V; Fox JL
    Anesthesiology; 1991 Mar; 74(3):446-54. PubMed ID: 2001023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro degradation of atracurium in human plasma.
    Merrett RA; Thompson CW; Webb FW
    Br J Anaesth; 1983 Jan; 55(1):61-6. PubMed ID: 6687375
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
    Nigrovic V; Banoub M
    Clin Pharmacokinet; 1992 May; 22(5):396-408. PubMed ID: 1505145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of atracurium in plasma by high-performance liquid chromatography.
    Stiller RL; Brandom BW; Cook DR
    Anesth Analg; 1985 Jan; 64(1):58-62. PubMed ID: 3838124
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of atracurium and laudanosine in human plasma by high-performance liquid chromatography.
    Varin F; Ducharme J; Besner JG; Théorêt Y
    J Chromatogr; 1990 Aug; 529(2):319-27. PubMed ID: 2229251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics.
    Farenc C; Audran M; Lefrant JY; Mazerm I; Bressolle F
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):117-26. PubMed ID: 10202964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolism and pharmacokinetics of atracurium].
    Colin JN; Singlas E
    Ann Fr Anesth Reanim; 1985; 4(6):465-70. PubMed ID: 2936284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure).
    Ward S; Neill EA
    Br J Anaesth; 1983 Dec; 55(12):1169-72. PubMed ID: 6689126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose).
    Ward S; Neill EA; Weatherley BC; Corall IM
    Br J Anaesth; 1983 Feb; 55(2):113-8. PubMed ID: 6687550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and kinetics of atracurium: an overview.
    Neill EA; Chapple DJ; Thompson CW
    Br J Anaesth; 1983; 55 Suppl 1():23S-25S. PubMed ID: 6688012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination.
    Fisher DM; Canfell PC; Fahey MR; Rosen JI; Rupp SM; Sheiner LB; Miller RD
    Anesthesiology; 1986 Jul; 65(1):6-12. PubMed ID: 3755306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of atracurium and laudanosine in dog plasma during cardiopulmonary bypass by high performance liquid chromatography with fluorometric detection].
    Yang Y; Chen M; Kuang Y; Ye L; Zhang W
    Se Pu; 2013 Jun; 31(6):572-6. PubMed ID: 24063198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro degradation of atracurium and cisatracurium at pH 7.4 and 37 degrees C depends on the composition of the incubating solutions.
    Weindlmayr-Goettel M; Kress HG; Hammerschmidt F; Nigrovic V
    Br J Anaesth; 1998 Sep; 81(3):409-14. PubMed ID: 9861132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium.
    Varin F; Ducharme J; Théorêt Y; Besner JG; Bevan DR; Donati F
    Clin Pharmacol Ther; 1990 Jul; 48(1):18-25. PubMed ID: 2369806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids.
    Sayer H; Quintela O; Marquet P; Dupuy JL; Gaulier JM; Lachâtre G
    J Anal Toxicol; 2004 Mar; 28(2):105-10. PubMed ID: 15068563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal failure on laudanosine excretion in man.
    Fahey MR; Rupp SM; Canfell C; Fisher DM; Miller RD; Sharma M; Castagnoli K; Hennis PJ
    Br J Anaesth; 1985 Nov; 57(11):1049-51. PubMed ID: 3840380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.